Explore the words cloud of the GLORIA project. It provides you a very rough idea of what is the project "GLORIA" about.
The following table provides information about the project.
|Coordinator Country||Netherlands [NL]|
|Total cost||5˙855˙219 €|
|EC max contribution||5˙855˙219 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2015-09-01 to 2021-08-31|
Take a look of project's partnership.
|1||STICHTING VUMC||NL (AMSTERDAM)||coordinator||1˙953˙483.00|
|2||CURVE CLINICAL BV||NL (AMSTERDAM DUIVENDRECHT)||participant||1˙909˙020.00|
|3||BLUEPHARMA - INDUSTRIA FARMACEUTICASA||PT (COIMBRA)||participant||479˙923.00|
|4||BEYONDEVICES LDA||PT (SOBRAL MONTE AGRAÇO)||participant||395˙719.00|
|5||LINICAL ACCELOVANCE EUROPE BV||NL ('S-HERTOGENBOSCH)||participant||314˙025.00|
|6||CENTRO HOSPITALAR E UNIVERSITARIO DE COIMBRA E.P.E.||PT (COIMBRA)||participant||198˙836.00|
|7||CHARITE - UNIVERSITAETSMEDIZIN BERLIN||DE (BERLIN)||participant||188˙180.00|
|8||UNIVERSITA DEGLI STUDI DI GENOVA||IT (GENOVA)||participant||184˙558.00|
|9||STICHTING TOOLS||NL (BUSSUM)||participant||96˙125.00|
|10||UNIVERSITATEA DE MEDICINA SI FARMACIE CAROL DAVILA DIN BUCURESTI||RO (BUCURESTI)||participant||88˙317.00|
|11||NARODNY USTAV REUMATICKYCH CHOROB-NURCH NIRD NATIONAL INSTITUTE OF RHEUMATIC DISEASES||SK (PIESTANY)||participant||23˙991.00|
|12||DEBRECENI EGYETEM||HU (DEBRECEN)||participant||23˙036.00|
|13||STICHTING VU||NL (AMSTERDAM)||participant||0.00|
GLORIA aims to prove that the addition of chronic low dose glucocorticoids (GC) to current antirheumatic therapy is highly cost-effective and safe in elderly patients with rheumatoid arthritis (RA). RA is a frequent (affecting > 2% of the elderly population), painful and disabling chronic disease with high societal costs. RA is associated with multiple comorbidities, polypharmacy and adverse events; these problems, together with challenges in compliance (adherence) are dramatically increased in the elderly population. About 50% of patients are chronically treated with low-dose glucocorticoids (GC) in combination with other antirheumatic drugs, but without good evidence on the balance of benefit and harm. Thus, existing guidelines and information on safety and efficacy of GC are inadequate. GLORIA will address these problems by conducting a large pragmatic trial: 800 elderly (>65y) RA patients receiving standard of care will be randomized to additionally receive 5 mg prednisolone daily or placebo for 2 years. Very liberal eligibility criteria will ensure representativeness to the target population, and most data will be collected from routine clinical practice, minimizing patient and physician load, and operating costs. A novel tool will monitor compliance; it can send personalized reminders to a patient’s smart device. The efficacy of this technology will be tested in a nested trial. Compliance and other characteristics will be entered into a model that will allow personalized risk and benefit assessment in the future. Qualitative research in patients and physicians of member states will explore expectations and challenges in guideline implementation. This information and the study results will enable an update to existing guidelines and patient information, in collaboration with guideline committees and regulatory agencies. Networking conferences will improve health technology assessment in the elderly in general.
|Reports on the progress of GLORIA project at European and American Rheumatology Annual Congresses (1)||Documents, reports||2020-04-22 09:57:24|
|Report on the educational activities and surveys conducted under GLORIA (1)||Documents, reports||2020-04-22 09:57:24|
|Report on analysis of existing guidelines and recommendations||Documents, reports||2020-04-22 09:57:24|
|Report on current status of the involvement of the elderly in clinical trials||Documents, reports||2020-04-22 09:57:24|
|Launch of a web-based survey of patientâ€™s opinions||Websites, patent fillings, videos etc.||2020-04-22 09:57:24|
|Written scientific documents addressing the limitations of current knowledge||Documents, reports||2020-04-22 09:57:24|
|Launch of web-based survey||Websites, patent fillings, videos etc.||2020-04-22 09:57:24|
|Scientific content with applicable lay versions made available at website.||Websites, patent fillings, videos etc.||2020-04-22 09:57:24|
Take a look to the deliverables list in detail: detailed list of GLORIA deliverables.
|year||authors and title||journal||last update|
Yannick Palmowski, Thomas Buttgereit, Christian Dejaco, Johannes W. Bijlsma, Eric L. Matteson, Marieke Voshaar, Maarten Boers, Frank Buttgereit
â€œOfficial Viewâ€ on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements
published pages: 1134-1141, ISSN: 2151-464X, DOI: 10.1002/acr.23185
|Arthritis Care & Research 69/8||2020-04-22|
Hartman, L; Rasch, La; Klausch, T; Bijlsma, Hwj; Christensen, R; Smulders, Ym; Ralston, Sh; Buttgereit, F; Cutolo, M; Da Silva JAP,; Opris, D; RovenskÃ½, J; Szamosi, S; Middelink, Lm; Lems, Wf; Boers, M.
Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial.
published pages: , ISSN: 1745-6215, DOI: 10.1186/s13063-017-2396-3
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLORIA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "GLORIA" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More
Global Alliance for Chronic Diseases SecretariatRead More